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ABSTRACT
Background: Vulvovaginal candidiasis (VVC) is the second most common vaginal infec-
tion. HIV-infection is a risk factor for this infection. Objective: To determine the frequency 
of VVC and to describe the main Candida species isolated and their susceptibility to antifun-
gal drugs in HIV-infected patients, compared to HIV-uninfected women in Salvador, Brazil. 
Methods: Cross-sectional study including a group of 64 HIV-infected women and 76 uninfect-
ed women, followed up at the AIDS reference center and at the Gynecological Clinic of Escola 
Bahiana de Medicina e Saúde Pública (Salvador, Bahia, Brazil). Results: Frequency of Candida spp. 
was higher in HIV-infected women (29.7%) than in HIV-uninfected controls (14.5%) (p = 0.02). 
The odds ratio value for vulvovaginal candidiasis in HIV-infected patients was 2.6 (95% CI: 
1.07 - 6.32 p = 0.03). Candida albicans was the most commonly isolated species in both HIV-infected 
(52.3%) and uninfected women (85.7%), followed by C. parapsolis in 17.6% and 14.3%, respectively. 
In HIV-infected women, C. glabrata, C. parapsilosis, and a coinfection of C. albicans and 
C. glabrata were also identified. There was no significant difference between Candida species 
isolated from the vaginal mucosa of women with VVC and colonization of the vaginal mucosa 
of HIV-infected and HIV-uninfected women. One C. glabrata isolate from an HIV-infected pa-
tient was resistant to fluconazole and other two isolates exhibited a dose-dependent susceptibility. 
Conclusion: Our results confirm a higher frequency of Candida spp. isolated from the vaginal mu-
cosa of HIV-infected women and a broader spectrum of species involved. Only Candida glabrata 
isolates showed decreased susceptibility to fluconazole.
Keywords: HIV; Candida; candidiasis, vulvovaginal.
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INTRODUCTION
Vulvovaginal candidiasis (VVC) is one of 
the most frequent vaginal infections in the 
world.1,2 It is estimated that 75% of women 
will have VVC at least once in their life-
time.3,4 Clinical signs and symptoms of 
this infection include itching, white dis-
charge, edema, and erythema of the vulva.4-6 
Candida albicans, a saprophyte present 
in the vaginal mucosa, is isolated in 80% 
of VVC cases.7,8 Factors which predispose to 
VVC include: pregnancy, uncontrolled dia-
betes mellitus, corticosteroids or systemic/
vaginal antibiotic therapy, HIV infection, 
and Candida vaginal colonization (CVC).9,10
The frequency of VVC caused by other Can-
dida species, such as Candida tropicalis, Can-
dida glabrata, and Candida krusei is increasing, 
especially in HIV-infected women.5,8,11 C. albi-
cans and C. glabrata are responsible for the 
majority of VVC cases in HIV-infected wom-
en.10,12 Although resistance to azoles antifun-
gal therapy is rare in C. albicans isolates (1%), 
it is becoming commonplace among C. glabra-
ta isolates (up to 15%) as well as among other 
non-albicans species.5,10,13,14
Few studies in Brazil have assessed the 
prevalence of VVC in HIV-infected women 
undergoing highly active antiretroviral ther-
apy (HAART) treatment.15 The aim of this 
study was to determine the frequency of VVC 
and to describe the main Candida species iso-
lated in HIV-infected patients, compared to 
HIV-uninfected women in Salvador, Brazil. In 
addition, the susceptibility of Candida species 
to antifungal drugs was evaluated.
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MATERIAL AND METHODS
Study population and procedure
A group of sixty-four HIV-infected women receiving care 
at the AIDS reference center of Bahia (Centro Especiali-
zado em Diagnóstico, Assistência e Pesquisa, CEDAP) and 
76 HIV-uninfected women from the Gynecology Clinic 
of Escola Bahiana de Medicina e Saúde Pública (Salvador, 
Bahia, Brazil) were included in this study, between May 
2006 and May 2007.
Patients were sequentially enrolled at the moment of 
the medical appointment. Inclusion criteria were wom-
en aged more than 18 years old, sexually active, posi-
tive serology for HIV (HIV group) or negative (control 
group). Exclusion criteria were: pregnancy or post-par-
tum, intra-vaginal treatment thirty days prior to vagi-
nal collection, vaginal bleeding, sexual intercourse or 
vaginal douching within the 48 hours preceding vaginal 
sample collection.
The study was approved by the Institutional Research 
Boarding of the Fundação Oswaldo Cruz Bahia (Fiocruz 
- Bahia). All patients signed an informed consent form 
prior to admission.
Specimen collection 
Demographic and clinical data were obtained by specific 
standardized data collection forms. CD4+ T lymphocytes 
count and HIV viral load values were obtained from medi-
cal records. Vaginal samples were collected with sterile 
swabs, during gynecological examination. Samples were cul-
tured on Sabouraud’s agar (BD-Difco), incubated at 35oC for 
48 h, and a direct examination was performed. Yeasts isolates 
were sub-cultured on CHROMagar Candida (Beckton Dick-
inson) in order to identify C. albicans and mixtures of yeasts. 
All C. albicans isolates were screened with Bichro-Dubli® (Fu-
mouze) in order to identify C. dubliniensis. Other Candida 
species were identified with ID32CAux® (BioMérieux). Mini-
mal inhibitory concentrations (MICs) were determined by 
the E-Test® method with C. parapsilosis ATCC 22019 as con-
trol. After 24 hours of incubation, an elliptical zone of inhibi-
tion was produced and the point at which the ellipse meets the 
strip gives a reading for the MIC of the drug.
Candida vaginal colonization was defined as culture 
isolation of yeasts from asymptomatic women. Women 
with a positive culture were considered to have VVC if they 
reported symptoms (vaginal itching, burning, and/or dis-
charge) at the time of the medical appointment.
Statistical analysis
Frequencies of Candida spp. of HIV-infected women 
were compared to those of the control group by using 
t tests for continuous variables and Chi-square tests 
or Fisher’s exact test for categorical variables. A mul-
tiple logistic regression model was used to evaluate the 
prediction capacity of each independent variable in 
the occurrence of the expected condition. Unadjusted 
odds ratios (ORs) were initially calculated to screen for 
inclusion in the multivariate model; variables that ex-
hibited at least moderate association (p = 0.10) with the 
outcome in the presence of these design variables were 
considered for inclusion in the final models. Statistical 
analysis was done with the SPSS (Statistical Package for 
the Social Sciences) 13.0.
RESULTS
The median age of HIV-infected patients was similar to that 
of the uninfected control group. Age at time of first sexual 
intercourse was lower in HIV-infected women (16.2 ± 4.0 
years) compared to the control group (17.5 ± 3.9 years) 
[p = 0.05]. The number of lifetime sexual partners and the 
frequency of reported sexually transmitted diseases were 
significantly higher in the HIV-infected group, compared 
to uninfected patients. Thirty-four HIV-infected women 
(56.3%) were treated with HAART. The mean CD4+ T lym-
phocytes count was 644 ± 551 cells/mm3 and mean HIV 
viral load was 3.9 ± 4.3 log10 copies/mL.
Candida spp. isolation from the vaginal mucosa was 
more frequent in HIV-infected patients (29.7%), com-
pared to uninfected women (14.5%) (p = 0.02). However, 
the frequency of VVC and Candida spp. colonization 
were similar in both HIV-infected and uninfected women 
(p = 0.95) (Table 1). The odds ratio value for the presence 
of Candida spp. in vaginal mucosa of HIV-infected pa-
tients was 2.6 (95% CI: 1.07 – 6.32, p = 0.03), after adjust-
ing for variables (Table 2).
Candida spp. identification was possible in 24 vagi-
nal samples (17 from HIV-infected patients and 7 from 
uninfected women) (Table 3). C. albicans was the most 
frequent species isolated in both HIV-infected (52.9%) 
and uninfected women (85.7%). In HIV-infected women 
were also identified the following species: C. glabrata, C. 
parapsilosis, C. dubliniensis and a coinfection of C. albi-
cans and C. glabrata. In the HIV-uninfected group, the 
only species isolated were C. albicans and C. parapsilosis.
In both HIV-infected and uninfected women, there 
was no significant difference observed in the frequency of 
a particular species of Candida isolated from the vaginal 
mucosa and the presence of VVC, nor was there a differ-
ence in the frequency of a particular species of Candida 
colonizing the vaginal mucosa (Table 4).
Only one out of 24 yeast isolates, an isolate of 
C. glabrata from an HIV-infected patient, was resistant to 
fluconazole (MIC > 256 mg/L). Two C. glabrata isolates 
exhibited a dose-dependent susceptibility to fluconazole 
(MIC = 24 and 48 mg/L) (Table 5).
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Table 1. Demographic characteristics and frequency of Candida spp. in HIV-infected and HIV-uninfected patients
 HIV-infected group (n = 64) HIV-uninfected group (n = 76) 
  n  n  p
Age (years)# 64 30.4 ± 6 76 28.7 ± 6 0.07
Marital status (n, %)     
 Married/cohabiting 34 53.1 47 61.8 0.29
 Unmarried/non-cohabiting 30 46.9 29 38.2 0.29
Education (n, %)     
 < 8 years 40 62.5 26 34.2 0.001
 > 8 years 24 37.5 50 65.8 0.001
Family income (n, %)     
 < $ 240/month 48 75 34 44.7 < 0.001
	 ≥	$	240/month	 16	 25	 42	 55.3	 <	0.001
Sexual and obstetric history     
 Age of first intercourse# 64 16.2 ± 4.0 76 17.5 ± 3.9 0.05
 No. of partners 64 8.3 ± 13.4 76 3.6 ± 4.3 < 0.01
 STD history (n, %) 26 40.6 % 10 13.2 < 0.01
 No. of deliveries 64 1.7 ± 1.2 76 1.3 ± 1.2 0.02
Users of HAART  38 59.4% - - NA
T CD4+ count 64 644 ± 551 - - NA
Viral load 64 3.9 ± 4.3 - - NA
Vaginal Candida spp. (n)  19 29.7 11 14.5 0.02
Candida spp. colonization 5 26.3 3 27.3 0.95
VVC 14 73.7 8 72.7 0.95
SD, standard deviation; NA, not applicable. STD, sexually transmitted disease. HAART, highly active antiretroviral therapy; CD4: 
cells/mm³; viral load: log10 copies/mL. p < 0.05, χ2 test, Student’s t test.
# mean ± SD
Table 2. Adjusted odds ratio for Candida spp.  
presence in HIV infected women
Variables Adjusted OR IC 95% p
HIV infection 2.61 1.07–6.32 0.03
Age 1.00 0.92–1.08 0.98
Years of schooling 0.89 0.78–1.02 0.1
Family income 0.97 0.7–1.33 0.86
First sexual 
1.02 0.91–1.14 0.73
 
intercourse
Condom use 0.82 0.27–2.43 0.72
Number of sexual 
0.99 0.95–1.04 0.9
 
partners
STD history 1.00 0.36–2.75 0.99
Adjusted variables: HIV infection, age, years of schooling, 
family income, first sexual intercourse, condom use, number 
of sexual partners, STD history. OR, odds ratio. p < 0.05. 
Multiple logistical regression.
DISCUSSION
This study assessed for the first time the prevalence of VVC 
and the main Candida species found in vaginal mucosa of 
HIV-infected women, in Salvador-Bahia, Brazil. The main 
finding of our study was the higher frequency of Can-
dida spp. in vaginal mucosa of HIV-infected women than 
HIV-uninfected, but the frequency of VVC was similar 
in both groups. These results were expected since the ma-
jority of the HIV-infected patients enrolled in this study 
were on HAART and had CD4+ T-cell counts higher than 
500 cells/mm3. Indeed, the risk of colonization with Candida 
species in HIV-infected women with CD4+ T-cell counts be-
low 200 cells/mm3 is three times higher, compared to immu-
nocompetent HIV-infected or HIV-uninfected women.16,17 
Similar prevalence of VVC (23.5%) was found in patients 
from a cohort of 458 HIV-infected patients under antiretro-
viral therapy followed in Rio de Janeiro-Brazil. However, the 
authors did not identify species of Candida and there was no 
Oliveira, Mascarenhas, Lacroix et al.
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Table 3. Frequency of Candida species isolated from the vaginal mucosa of HIV-infected and uninfected women
 HIV-infected women HIV-uninfected women  
 n = 17 n = 7
Isolated species  n % n % p = 0.56
C. albicans 9 52.9 6 85.7 
C. parapsilosis 3 17.6 1 14.3 
C. glabrata 3 17.6 0 0 
C. dubliniensis 1 5.9 0 0 
C. albicans and C. glabrata 1 5.9 0 0 
p < 0.05, χ2 test.
Table 4. Frequency of vulvovaginal candidiasis and colonization with Candida species from the vaginal mucosa 
of HIV-infected and uninfected women
 HIV-infected HIV-uninfected 
 n = 17 n = 7
Candida species  VVC Colonization VVC Colonization 
 n n n n 
C. albicans 7 2 5 1
C. parapsilosis 2 1 1 0
C. glabrata 1 2 0 0
C. dubliniensis 1 0 0 0
C.albicans + C. glabrata 1 0 0 0
VVC, vulvovaginal candidiasis. p < 0.05, χ2 test, Fisher’s exact test.
Table 5. Minimal inhibitory concentrations (mg/L) of Candida spp.
Candida species        MIC median, mg/L, (min-max) 
 n = 25
 Amphotericin B Flucytosine Fluconazole Voriconazole Caspofungin
C. albicans 0.22 0.5 0.25 0.008 0.11 
(n = 16) (0.094-0.38) (0.023- > 32) (0.094-0.5) (0.004-0.032) (0.064-0.5)
C. dubliniensis 0.064 0.004 0.094 0.006 0.19 
(n = 1)     
C. glabrata 0.5 0.007 36 0.285 0.19 
(n = 4) (0.38-0.5) (0.006-0.008) (8- > 256) (0.064-1) (0.19-0.38)
C. parapsilosis 0.38 0.023 0.285 0.007 0.56 
(n = 4) (0.25-0.38) (0.012-0.023) (0.19-0.5) (0.006-0.016) (0.25-1)
Candida species from vaginal mucosa
243Braz J Infect Dis 2011; 15(3):239-244
uninfected-control group.15 The prevalence of Candida spp. 
isolated from the vaginal mucosa is variable. In Italy, 16.8% 
of HIV-infected women have Candida spp. in vaginal muco-
sa,10 while in the United States 35% of HIV-infected women 
had vaginal positive culture for Candida spp. (EUA).18 Such 
variation could be explained by differences in the immune 
status of patients involved or by the presence of additional 
risk factors to Candida infection, such as a decreased num-
ber of CD4+ T-cells or concomitant antibiotic therapy.18
There is scant information about the frequency of non-al-
bicans species in vaginal mucosa of HIV-infected women in 
Brazil. In the present study, C. albicans was the most frequent 
species isolated from the vaginal mucosa in both HIV-infect-
ed and uninfected women. In other countries such as Italy 
and the United States, the frequency was higher ranging from 
81% to 92%, compared to that found in our study (52.9%).10,11,18 
In HIV-uninfected patients, our data was similar to other 
studies performed in Brazil, which describe the prevalence 
of C. albicans isolated in vaginal samples ranging from 60% 
to 80%19,20 and in other countries where the prevalence of 
C. albicans in vaginal samples ranges between 80% to 
90%.1,11,21,22 A higher diversity of non-albicans species was 
found in HIV-infected patients compared to uninfected con-
trols. C. glabrata was the most frequent non-albicans species 
isolated in HIV-infected patients, followed by C. parapsilosis. 
In accordance with other studies, there was no relation-
ship found between symptoms and isolated yeast species.23 
No correlation could be established between the level of 
CD4+ T-cell counts, the amount of HIV viral load, and the 
frequency of VVC in HIV-infected patients. These results 
were expected because of the observational nature of our 
study and the small sample size.
Regarding the susceptibility of Candida species to antifun-
gal drugs, isolated yeasts were susceptible to Amphotericin B, 
Flucytosine, Voriconazole, and Caspofungin. Only three iso-
lates had dose-dependent susceptibility or resistance to flucon-
azole, all of these were C. glabrata present in the vaginal mu-
cosa of HIV-1-infected patients. These data are in agreement 
with other studies23-25 that described azole refractory vaginitis 
caused by non-albicans Candida, particularly by C. glabrata.23 
Non-albicans Candida infections frequently require the use of 
non-azole therapy, including topical therapy with boric acid, 
Flucytosine, or Amphotericin B.24,26
In summary, our study found higher prevalence of 
Candida spp. in vaginal mucosa of HIV-infected patients 
than uninfected women. Thus, these patients could ben-
efit from a periodic gynecological examination and VVC 
screening, even when undergoing HAART treatment. 
Although the species of C. albicans is the most frequent, 
it is evident the emergence of non-albicans Candida spe-
cies, including C. glabrata with intrinsic resistance to 
azoles. Therefore, alternative agents to treat VCC caused 
by C. glabrata should be considered. 
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